Analysis BioNTech Hands Gilead the Chemo Slot in ROSETTA Breast-01 — A Trial Design, Not a Verdict
BioNTech has redrawn the blueprint for one of its flagship breast cancer trials, and the change is procedural rather than clinical. Under an agreement with Gilead Sciences, the German biotech...